Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study

Casalone, Elisabetta; Birolo, Giovanni; Pardini, Barbara; Allione, Alessandra; Russo, Alessia; Catalano, Chiara; Ferrante, Daniela; Magnani, Corrado; Sculco, Marika; Dianzani, Irma; Grosso, Federica; Mirabelli, Dario; Filiberti, Rosa Angela; Rena, Ottavio; Sacerdote, Carlotta; Rodriguez‐Barranco, Miguel; Smith‐Byrne, Karl; Panico, Salvatore; Agnoli, Claudia; Johnson, Theron; Kaaks, Rudolf; Tumino, Rosario; Huerta, José María; Riboli, Elio; Heath, Alicia K.; Trobajo-Sanmartín, Camino; Schulze, Matthias B.; Saieva, Calogero; Amiano, Pilar; Agudo, Antonio; Weiderpass, Elisabete; Víneis, Paolo; Matullo, Giuseppe

doi:10.3390/cancers15010125

Cited by 5 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SMRP has been associated by others with similar findings. SMRP levels were elevated in only 50% of mesothelioma patients, but were not elevated in sarcomatous cases ( 108 ). Thus, a single diagnostic marker could not be justified.…”

Section: Multiple Therapies For Mesothelioma Managementmentioning

confidence: 98%

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

et al. 2023

View full text Add to dashboard Cite

The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma.

show abstract

Section: Multiple Therapies For Mesothelioma Managementmentioning

confidence: 98%

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Circulating miRNAs have attracted a great deal of interest as potential diagnostic biomarkers because of their stability and detectability. miRNAs derived from extracellular vesicles (EVs) ( 54 ) and exosomes ( 153 ) may reflect a miRNA signature that may resemble a very early disease condition ( 154 ). For instance, miR-126 overexpressed in AITL signifies poor prognosis, and its enrichment in the exosome is found to distinguish early and advanced non-small cell lung cancer (NSCLC), while it is downregulated for advanced NSCLC ( 155 ).…”

Section: Applicability Of Mirna-based Diagnosis and New Avenuesmentioning

confidence: 99%

Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles

et al. 2023

View full text Add to dashboard Cite

T-cell malignancy is a broad term used for a diverse group of disease subtypes representing dysfunctional malignant T cells transformed at various stages of their clonal evolution. Despite having similar clinical manifestations, these disease groups have different disease progressions and diagnostic parameters. The effective diagnosis and prognosis of such a diverse disease group demands testing of molecular entities that capture footprints of the disease physiology in its entirety. MicroRNAs (miRNAs) are a group of noncoding RNA molecules that regulate the expression of genes and, while doing so, leave behind specific miRNA signatures corresponding to cellular expression status in an altered stage of a disease. Using miRNAs as a diagnostic tool is justified, as they can effectively distinguish expressional diversity between various tumors and within subtypes of T-cell malignancies. As global attention for cancer diagnosis shifts toward liquid biopsy, diagnosis using miRNAs is more relevant in blood cancers than in solid tumors. We also lay forward the diagnostic significance of miRNAs that are indicative of subtype, progression, severity, therapy response, and relapse. This review discusses the potential use and the role of miRNAs, miRNA signatures, or classifiers in the diagnosis of major groups of T-cell malignancies like T-cell acute lymphoblastic lymphoma (T-ALL), peripheral T-cell lymphoma (PTCL), extranodal NK/T-cell lymphoma (ENKTCL), and cutaneous T-cell lymphoma (CTCL). The review also briefly discusses major diagnostic miRNAs having prominent metabolic roles in these malignancies to highlight their importance among other dysregulated miRNAs.

show abstract

Melodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesothelioma

Abd-Elmawla,

Abdel Mageed,

AL-Noshokaty

et al. 2023

Pathology - Research and Practice

View full text Add to dashboard Cite

Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study

Cited by 5 publications

References 53 publications

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

Diagnostic significance of dysregulated miRNAs in T-cell malignancies and their metabolic roles

Melodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesothelioma

Contact Info

Product

Resources

About